教授

    • 姓名:廖晨钟
    • 职务:
    • 职称:教授
    • 所属系:药物科学与工程系
    • 邮箱:czliao@hfut.edu.cn
    • 办公地点:
  • 个人简介
  • 研究领域
  • 科研项目
  • 学术成果
  • 荣誉奖项


学习经历

2001/9–2004/7,中国科学院,博士

1995/9–1998/6,北京工业大学,硕士

1991/9–1995/7,青岛科技大学,学士


工作经历

2012/10-至今,合肥工业大学,生物与医学工程学院,教授

2010/10-2012/9,University of Michigan,Medical School,Research Scientist

2005/10-2010/9,National Institutes of Health,National Cancer Institute,博士后

2004/7-2005/8,深圳微芯生物科技有限责任公司,生化信息学部,主任

1998/7-2001/8,北京工业大学出版社,图书编辑


职务: 职称: 教授
所属系: 药物科学与工程系 邮箱: czliao@hfut.edu.cn
办公地点: 学术成果 <br>发表的期刊论文
<br>1、Developing Polo-Like Kinase 1 Inhibitors. Future Medicinal Chemistry, 2020, 12, 869-871.(通讯作者)<br>
<br>2、Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1/histone deacetylase-1 inhibitors. Bioorganic & Medicinal Chemistry Letters, 2020, 30, 127036.(通讯作者)<br>
<br>3、Discovery and development of plasma kallikrein inhibitors for multiple diseases. European Journal of Medicinal Chemistry, 2020,190, 112137.(通讯作者)<br>
<br>4、Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library. European Journal of Medicinal Chemistry, 2020,189, 112023.<br>
<br>5、Discovery and Characterization of 2,5-Substituted Benzoic Acid Dual Inhibitors of the Anti-apoptotic Mcl-1 and Bfl-1 Proteins. Journal of Medicinal Chemistry, 2020,63, 2489-2510.<br>
<br>6、LongShengZhi Capsule Inhibits Doxorubicin-Induced Heart Failure by Anti-Oxidative Stress. Biomedicine & Pharmacother, 2020, 123, 109803.<br>
<br>7、Discovery of Class I Histone Deacetylase Inhibitors Based on Romidpesin With Promising Selectivity for Cancer Cells. Future Medicinal Chemistry, 2020, 12, 311-323.<br>
<br>8、Structure-based Design and SAR Development of Novel Selective Polo-Like Kinase 1 Inhibitors Having the Tetrahydropteridin Scaffold. European Journal of Medicinal Chemistry, 2019, 184, 111769.(通讯作者)<br>
<br>9、Developments in Inhibiting Platelet Aggregation Based on Different Design Strategies. Future Medicinal Chemistry, 2019, 11, 1757-1775.(通讯作者)<br>
<br>10、Discovery and Development of Cyclin-Dependent Kinase 8 Inhibitors. Current Medicinal Chemistry, 2019, DOI: 10.2174/0929867326666190402110528.<br>
<br>11、Design, synthesis and biological evaluation of novel human monoamine oxidase B inhibitors based on a fragment in an X-ray crystal structure. Bioorganic & Medicinal Chemistry Letters, 2019, 29, 1012-1018.(通讯作者)<br>
<br>12、Discovery of novel 2,3-dihydro-1H-inden-1-amine derivatives as selective monoamine oxidase B inhibitors. Bioorganic & Medicinal Chemistry Letters, 2019, 29, 1090-1093.(通讯作者)<br>
<br>13、Discovery of Mcl-1 inhibitors from integrated high throughput and virtual screening. Scientific Reports, 2018, 8, 10210.(并列第一作者)<br>
<br>14、The selectivity and bioavailability improvement of novel oral anticoagulants: An overview. European Journal of Medicinal Chemistry, 2018,146, 299-317.(通讯作者)<br>
<br>15、Design, Synthesis and Bioevalucation of Novel 2,3-Dihydro-1H-inden-1-amine Derivatives as Potent and Selective Human Monoamine Oxidase B Inhibitors Based on Rasagiline. European Journal of Medicinal Chemistry, 2018,145, 588-593.(通讯作者)<br>
<br>16、Design, synthesis, and biological evaluation of novel highly selective polo-like kinase 2 inhibitors based on the tetrahydropteridin chemical scaffold. European Journal of Medicinal Chemistry, 2018,143, 724-731.(通讯作者)<br>
<br>17、甲氨蝶呤缓释植入剂延迟小鼠肉瘤复发的研究. 中国新药杂志, 2017, 26, 2828-3834.(通讯作者)<br>
<br>18、Progress in the Discovery of Macrocyclic Histone Deacetylase Inhibitors for the Treatment of Cancer. Current Medicinal Chemistry,2017, 24, 4166-4179.(通讯作者)<br>
<br>19、nhibition of Pax2 Transcription Activation with a Small Molecule that Targets the DNA Binding Domain. ACS Chemical Biology. 2017, 12, 724-734.<br>
<br>20、Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities. Journal of Medicinal Chemistry, 2016, 59, 5766-5779.(并列第一作者)<br>
<br>21、From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway. Drug Discovery Today, 2016, 21, 1027-1036.(通讯作者)<br>
<br>22、Novel tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one: Design, synthesis, model and use as hMAO-B inhibitors. Bioorganic & Medicinal Chemistry,2016, 24, 1741-1748.(通讯作者)<br>
<br>23、Identification of human telomerase inhibitors having the core of N-acyl-4,5-dihydropyrazole with anticancer effects. Bioorganic & Medicinal Chemistry Letters,2016, 26, 1508-1511.(通讯作者)<br>
<br>24、Chemical Structure Similarity Search for Ligand-Based Virtual Screening: Methods and Computational Resources. Current Drug Targets. 2016, 17, 1580 - 1585.<br>
<br>25、Perspectives in Medicinal Chemistry: Metalloprotein Inhibitors: What Have We Made and What is the Next Step? Current Topics in Medicinal Chemistry. 2016, 16, 467-469.(通讯作者)<br>
<br>26、Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in vitro and in vivo Antitumor Activities. Journal of Medicinal Chemistry, 2015, 58, 7672-7680.<br>
<br>27、Metalloprotein Inhibitors for the Treatment of Human Diseases. Current Topics in Medicinal Chemistry, 2016, 16, 384-396.(通讯作者)<br>
<br>28、Editorial: Current Progress in the Development of Metalloprotein Inhibitors. Current Topics in Medicinal Chemistry, 2016, 16, 383.(通讯作者)<br>
<br>29、Novel HIV-1 Integrase Inhibitor Development by Virtual Screening Based on QSAR Models. Current Topics in Medicinal Chemistry, 2016, 16, 441-448.<br>
<br>30、Ma N, Luo Y, Wang Y, Liao C, Ye WC, Jiang S. Selective histone deacetylase inhibitors with anticancer activity. Current Topics in Medicinal Chemistry, 2016, 16, 415-426.<br>
<br>31、Novel 2H-chromen-2-one Derivatives of Resveratrol: Design, Synthesis, Modeling and Use as Human Monoamine Oxidase Inhibitors. European Journal of Medicinal Chemistry, 2015,103, 185-190.(通讯作者)<br>
<br>32、Synthesis, Characterization and Antitumor Activity of Novel Ferrocene-Based Amides Bearing Pyrazolyl Moiety. Journal of Inorganic and Organometallic Polymers and Materials, 2015, 25, 419-426.<br>
<br>33、Discovery and Pharmacophore Studies of Novel Pyrazole-Based Anti-Melanoma Agents. CHEMISTRY & BIODIVERSITY, 2015, 12, 116-132.(通讯作者)
<br>34、药物分子设计中的大数据问题. 科学通报, 2015, 60, 558-565.<br>
<br>35、Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors. European Journal of Medicinal Chemistry, 2014, 86, 639-652.(并列第一作者)<br>
<br>36、3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation.Journal of Medicinal Chemistry, 2014. 57, 4111-4133.<br>
<br>37、A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo. Molecular Cancer Therapeutics, 2014, 13, 565-575.(并列第一作者)<br>
<br>38、Diversity evolution and jump of Polo-like kinase 1 inhibitors. Science China Chemistry, 2013, 56, 1392-1401.(通讯作者)<br>
<br>39、Biological evaluation of 2-methylpyrimidine derivatives as active pan Bcr-Abl inhibitors. Science China Chemistry, 2014, 57, 823-832.<br>
<br>40、Targeting recruitment of Disruptor Of Telomeric silencing 1-Like (DOT1L): Characterizing the interactions between DOT1L and MLL-fusion proteins. Journal of Biological Chemistry, 2013, 288, 30585-30596.<br>
<br>41、PDB Ligand Conformational Energies Calculated Quantum-Mechanically. Journal of Chemical Information and Modeling, 2012, 52, 739-756.<br>
<br>42、Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review. Expert Opinion on Therapeutic Patents, 2012,22, 37-55.
<br>43、Software and Resources for Computational Medicinal Chemistry. Future Medicinal Chemistry, 2011, 3, 1123-1140.(第一作者,通讯作者)
<br>44、Discovery of a Novel Hybrid from Finasteride and Epristeride as 5α-reductase Inhibitor. Bioorganic & Medicinal Chemistry Letters, 2011, 21, 475-478.(通讯作者)<br>
<br>45、Probing Binding Modes of Small Molecule Inhibitors to the Polo-Box Domain of Human Polo-like Kinase 1. ACS Medicinal Chemistry Letters, 2010, 1, 110-114.(第一作者)<br>



<br>参编学术专著及教材

<br>1、《药物设计学》,中国医药科技出版社,2016.

<br>2、Molecular docking and structure-based virtual screening. In “In Silico Drug Discovery and Design Techniques”. (ISBN: 978-1-909453-02-9). Invited book chapter, Future Science Group, 2013, 7-22.

<br>3、HIV-1 integrase-DNA models. In “HIV-1 Integrase: Mechanism of Action and Inhibitor Design”. Invited book chapter, John Wiley & Sons, Inc. 2011, 429-455.

<br>4、An integrated biochemoinformatics system for drug discovery: managing and mining chemical structure information, biological activity fingerprints, and gene expression profiling patterns. In “Frontiers of Biochip Technologies”, Xing WL and Cheng J (Editors), Springer US, Invited book chapter, 2006, 191-206.
研究领域 <br>1、药物设计与合成

<br>2、计算机辅助药物设计
<br>3、化学信息学
<br>4、恶性肿瘤药物、神经退行性疾病药物、抗艾滋病药物的研发
科研项目 <br>1.《共价/非共价Polo-like Kinase 2抑制剂的设计、合成及其抗帕金森氏症的机理研究》,国家自然科学基金面上项目,项目批准号:21672050,2017/01 – 2020/12,65万元,在研,主持

<br>2.《选择性识别端粒蛋白p65的苯并吡喃新先导:优化设计合成及作用机制》,国家自然科学基金面上项目,项目批准号:21572003,2016/01 – 2019/12,65万元,在研,参加

<br>3.《基于结构的髓样细胞白血病-1抑制剂设计、结构优化及抗肿瘤活性研究》,合肥工业大学春华计划(中央高校基本科研业务费专项资金资助),编号:2013HGCH0015,2013/05 – 2014/12,30万元,主持

<br>4.合肥工业大学人才引进基金
荣誉奖项 <br>1.安徽省药学会药物化学专业委员会副主任委员

<br>2.美国国家健康研究院癌症研究所(National Institutes of Health, National Cancer Institute)客座研究员(Guest Researcher)

<br>3.美国化学会(American Chemical Society)会员

<br>4.美国癌症研究协会(American Association for Cancer Research)会员

<br>5.多家国际知名杂志,如ACS Medicinal Chemistry Letters, Journal of Medicinal Chemistry, Journal of Chemical Information and Modeling, Future Medicinal Chemistry, Bioorganic & Medicinal Chemistry Letters, Bioorganic & Medicinal Chemistry, Antiviral Research, Journal of Chemical Theory and Computation, Current Topics in Medicinal Chemistry, Current Medicinal Chemistry, PLoS Computational Biology, Molecular Informatics, Letters in Drug Design & Discovery, Journal of Biophysics and Structural Biology等的特约审稿人

<br>6.香港特区政府总部食物及卫生局科研基金的特约评审人

<br>7.担任Current Topics in Medicinal Chemistry杂志的Guest Editor,主编过一期特刊《Current Progress in the Development of Metalloprotein Inhibitors》

上一条:李兴江 下一条:刘 咏

关闭

电话:0551-62901285邮箱:spxy@hfut.edu.cn

邮编:230601地址:安徽省合肥市经济技术开发区大学城翡翠路420号

扫一扫

学院官方公众号